Michael Xiang, Ting Martin Ma, Ricky Savjani, Erqi L Pollom, R Jeffrey Karnes, Tristan Grogan, Jessica K Wong, Giovanni Motterle, Jeffrey J Tosoian, Bruce J Trock, Eric A Klein, Bradley J Stish, Robert T Dess, Daniel E Spratt, Avinash Pilar, Chandana Reddy, Rebecca Levin-Epstein, Trude B Wedde, Wolfgang A Lilleby, Ryan Fiano, Gregory S Merrick, Richard G Stock, D Jeffrey Demanes, Brian J Moran, Hartwig Huland, Phuoc T Tran, Santiago Martin, Rafael Martinez-Monge, Daniel J Krauss, Eyad I Abu-Isa, Ridwan Alam, Zeyad Schwen, Thomas M Pisansky, C Richard Choo, Daniel Y Song, Stephen Greco, Curtiland Deville, Todd McNutt, Theodore L DeWeese, Ashley E Ross, Jay P Ciezki, Paul C Boutros, Nicholas G Nickols, Prashant Bhat, David Shabsovich, Jesus E Juarez, Natalie Chong, Patrick A Kupelian, Matthew B Rettig, Nicholas G Zaorsky, Alejandro Berlin, Jonathan D Tward, Brian J Davis, Robert E Reiter, Michael L Steinberg, David Elashoff, Eric M Horwitz, Rahul D Tendulkar, Derya Tilki, Johannes Czernin, Andrei Gafita, Tahmineh Romero, Jeremie Calais, Amar U Kishan
IMPORTANCE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear. OBJECTIVES: To evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocalized upstaging on PSMA PET/CT and to compare its performance with existing risk-stratification tools...
December 1, 2021: JAMA Network Open